170 related articles for article (PubMed ID: 24842891)
1. Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
Dewaraja YK; Schipper MJ; Shen J; Smith LB; Murgic J; Savas H; Youssef E; Regan D; Wilderman SJ; Roberson PL; Kaminski MS; Avram AM
J Nucl Med; 2014 Jul; 55(7):1047-53. PubMed ID: 24842891
[TBL] [Abstract][Full Text] [Related]
2. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
Dewaraja YK; Schipper MJ; Roberson PL; Wilderman SJ; Amro H; Regan DD; Koral KF; Kaminski MS; Avram AM
J Nucl Med; 2010 Jul; 51(7):1155-62. PubMed ID: 20554734
[TBL] [Abstract][Full Text] [Related]
3. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
4. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
Koral KF; Dewaraja Y; Li J; Lin Q; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2003 Mar; 44(3):457-64. PubMed ID: 12621015
[TBL] [Abstract][Full Text] [Related]
5. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
[TBL] [Abstract][Full Text] [Related]
6. Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations.
Howard DM; Kearfott KJ; Wilderman SJ; Dewaraja YK
Cancer Biother Radiopharm; 2011 Oct; 26(5):615-21. PubMed ID: 21939358
[TBL] [Abstract][Full Text] [Related]
7. Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.
Roberson PL; Smith LB; Morgan MA; Schipper MJ; Wilderman SJ; Avram AM; Kaminski MS; Dewaraja YK
Cancer Biother Radiopharm; 2017 Nov; 32(9):309-319. PubMed ID: 29083933
[TBL] [Abstract][Full Text] [Related]
8. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
[TBL] [Abstract][Full Text] [Related]
9. Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.
Hobbs RF; Baechler S; Wahl RL; He B; Song H; Esaias CE; Frey EC; Jacene H; Sgouros G
J Nucl Med; 2010 Mar; 51(3):368-75. PubMed ID: 20150265
[TBL] [Abstract][Full Text] [Related]
10. Pre-dosing with lilotomab prior to therapy with
Stokke C; Blakkisrud J; Løndalen A; Dahle J; Martinsen ACT; Holte H; Kolstad A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1233-1241. PubMed ID: 29470615
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.
Ferrer L; Malek E; Bodet-Milin C; Legouill S; Prangère T; Robu D; Jeans S; Tipping J; Huglo D; Carpentier P; Illidge T; Kraeber-Boderé F; Morschhauser F; Bardiès M
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):529-37. PubMed ID: 23358406
[TBL] [Abstract][Full Text] [Related]
12. Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy.
Amro H; Wilderman SJ; Dewaraja YK; Roberson PL
J Nucl Med; 2010 Apr; 51(4):654-9. PubMed ID: 20237032
[TBL] [Abstract][Full Text] [Related]
13. Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.
Dewaraja YK; Wilderman SJ; Koral KF; Kaminski MS; Avram AM
Cancer Biother Radiopharm; 2009 Aug; 24(4):417-26. PubMed ID: 19694576
[TBL] [Abstract][Full Text] [Related]
14. Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method.
Koral KF; Francis IR; Kroll S; Zasadny KR; Kaminski MS; Wahl RL
Cancer; 2002 Feb; 94(4 Suppl):1258-63. PubMed ID: 11877754
[TBL] [Abstract][Full Text] [Related]
15. Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity.
Schipper MJ; Koral KF; Avram AM; Kaminski MS; Dewaraja YK
Cancer Biother Radiopharm; 2012 Sep; 27(7):403-11. PubMed ID: 22947086
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
[TBL] [Abstract][Full Text] [Related]
17. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
[TBL] [Abstract][Full Text] [Related]
18. Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
Roberson PL; Amro H; Wilderman SJ; Avram AM; Kaminski MS; Schipper MJ; Dewaraja YK
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):874-83. PubMed ID: 21174088
[TBL] [Abstract][Full Text] [Related]
19. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
Boucek JA; Turner JH
Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
[TBL] [Abstract][Full Text] [Related]
20. A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
Siegel JA; Kroll S; Regan D; Kaminski MS; Wahl RL
J Nucl Med; 2002 Mar; 43(3):354-63. PubMed ID: 11884495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
